Dark-horse ALS player touts open-label survival data after mid-stage flop, with platform study due soon

Kyle LaHucik

Senior Reporter

Eight months after missing the primary and secondary endpoints on a mid-stage test of its ALS drug, Clene Nanomedicine is back with new data showing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Dark-horse ALS player touts open-label survival data after mid-stage flop, with platform study due soon

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Will CRISPR matter?

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Dark-horse ALS play­er touts open-la­bel sur­vival da­ta af­ter mid-stage flop, with plat­form study due soon

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

Will CRISPR mat­ter?

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

Dark-horse ALS player touts open-label survival data after mid-stage flop, with platform study due soon

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Will CRISPR matter?

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence